Payment overview · 2025
General Payments
$60.71
3 reported records · 3 companies
Healthcare provider profile · identity verified
Laura Allison Hunt, MD
Allopathic & Osteopathic Physicians|Family Medicine · EASLEY, SC · NPI 1780606780
Verified facts
What the public records show
CMS Open Payments records show Laura Allison Hunt, MD received $60.71 in general payments during 2025 across 3 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.09 | 39.7% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $21.49 | 35.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.13 | 24.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $60.71 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 97 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 428 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 348 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 346 | 96 |
| Gabapentin | Gabapentin | 312 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 294 | 90 |
| Lisinopril | Lisinopril | 292 | 87 |
| Omeprazole | Omeprazole | 272 | 79 |
| Trazodone Hcl | Trazodone Hcl | 256 | 70 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 229 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 65 |
| Famotidine | Famotidine | 215 | 68 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 211 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 210 | 84 |
| Lorazepam | Lorazepam | 208 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 207 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 195 | 51 |
| Sertraline Hcl | Sertraline Hcl | 194 | 47 |
| Metformin Hcl Er | Metformin Hcl | 180 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 53 |
| Alprazolam | Alprazolam | 175 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 163 | 49 |
| Furosemide | Furosemide | 163 | 48 |
| Montelukast Sodium | Montelukast Sodium | 162 | 49 |
| Spironolactone | Spironolactone | 159 | 51 |
| Clonazepam | Clonazepam | 145 | 22 |
| Pregabalin | Pregabalin | 145 | 25 |
| Baclofen | Baclofen | 136 | 40 |
| Metformin Hcl | Metformin Hcl | 128 | 38 |
| Estradiol | Estradiol | 119 | 33 |
| Bupropion Xl | Bupropion Hcl | 117 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 116 | 40 |
| Mounjaro | Tirzepatide | 114 | 21 |
| Potassium Chloride | Potassium Chloride | 111 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 37 |
| Losartan Potassium | Losartan Potassium | 106 | 32 |
| Ozempic | Semaglutide | 106 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 105 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 102 | 35 |
| Meloxicam | Meloxicam | 99 | 30 |
| Jardiance | Empagliflozin | 97 | 27 |
| Allopurinol | Allopurinol | 96 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 33 |
| Fluconazole | Fluconazole | 90 | 32 |
| Azelastine Hcl | Azelastine Hcl | 88 | 36 |
| Tramadol Hcl | Tramadol Hcl | 87 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 24 |
| Aripiprazole | Aripiprazole | 74 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 74 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 74 | 21 |
| Glimepiride | Glimepiride | 73 | 25 |
| Naproxen | Naproxen | 72 | 16 |
| Promethazine Hcl | Promethazine Hcl | 70 | 18 |
| Ondansetron Odt | Ondansetron | 69 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 22 |
| Buspirone Hcl | Buspirone Hcl | 65 | 14 |
| Diazepam | Diazepam | 65 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 17 |
| Simvastatin | Simvastatin | 63 | 16 |
| Ezetimibe | Ezetimibe | 62 | 23 |
| Valacyclovir | Valacyclovir Hcl | 56 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 13 |
| Celecoxib | Celecoxib | 52 | 17 |
| Cephalexin | Cephalexin | 52 | 35 |
| Mirtazapine | Mirtazapine | 52 | 12 |
| Nystatin | Nystatin | 52 | 14 |
| Carvedilol | Carvedilol | 49 | 12 |
| Risedronate Sodium | Risedronate Sodium | 49 | 15 |
| Lidocaine | Lidocaine | 48 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 18 |
| Chlorthalidone | Chlorthalidone | 46 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Irbesartan | Irbesartan | 46 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 45 | 14 |
| Lamotrigine | Lamotrigine | 44 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 19 |
| Meclizine Hcl | Meclizine Hcl | 44 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Prednisone | Prednisone | 41 | 33 |
| Temazepam | Temazepam | 41 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 21 |
| Amoxicillin | Amoxicillin | 38 | 35 |
| Azithromycin | Azithromycin | 38 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 12 |
| Topiramate | Topiramate | 36 | suppressed |
| Eliquis | Apixaban | 35 | 15 |
| Colchicine | Colchicine | 33 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 20 |
| Alendronate Sodium | Alendronate Sodium | 28 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 24 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 11 |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Nadolol | Nadolol | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 12 |
| Eplerenone | Eplerenone | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dupixent Pen | Dupilumab | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $60.71 · 3 records | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE, Ozempic, Rybelsus, Tyvaso | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error